CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

SensbiosysWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug1775 Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances Wiki 0.71

Correlated MeSH Terms (5)

Name (Synonyms) Correlation
D004408 Dysgeusia NIH 0.58
D000857 Olfaction Disorders NIH 0.29
D007239 Infection NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0000458 Anosmia HPO 0.29

There is one clinical trial.

Clinical Trials

1 Remote Blood Pressure Monitoring With the Wearable SENBIOSYS Photoplethysmographic Device

During the last couple of years, a growing number of wearable devices evolved to provide accurate, cheap and non-invasive monitoring of vitals parameters.This connected care technology could be helpful for treatment and care during a pandemic such as COVID-19. The use of these non-invasive remote monitoring devices can help health care providers to assess patient's vital signs and symptom progression, reducing reducing patient and healthcare provider contact and exposure to COVID-19 during this pandemic.

NCT04379986 Blood Pressure Device: Sensbiosys

Primary Outcomes

Description: The primary outcome is the assessment of mean bias (± 95% CI or precision of bias) for systolic blood pressure (SBP), diastolic blood pressure (DBP) and mean blood pressure (MBP) between invasive and non-invasive BP measurements. The standard deviation of the bias (±95% limits of agreement), will be assessed for SBP, DBP, and MBP measurements.

Measure: Feasibility of non-invasive BP monitors: blood pressure

Time: 10 to 15 minutes per patient (once)

Secondary Outcomes

Description: Secondary outcomes include reliability index (Qualification Index QI) for blood pressure epochs and count of qualified epochs.

Measure: Percentage of signal with artefact,

Time: 10 to 15 minutes per patient (once)

No related HPO nodes (Using clinical trials)